Brain Tumor Clinical Trials

Study: 2018-0044
Phase II
Treatment agent(s): GDC-0084
Newly diagnosed MGMT unmethylated glioblastoma 
NIH link: NCT No: NCT03522298

Study: 2017-0555
Phase I
Treatment agent(s): EDO-S101, radiation
Newly diagnosed MGMT unmethylated, IDH wildtype glioblastoma 
This trial is only available at MD Anderson
NIH link: NCT No: NCT03452930

Study: 2016-0867
Phase I/II
Treatment agent(s): Atezolizumab, radiation, Temozolomide
Newly diagnosed glioblastoma 
This trial is only available at MD Anderson
NIH link: NCT No: NCT03174197

Study: 2014-0899
Phase I/II
Treatment agent(s): CMV-stimulated adoptive T cells,Temozolomide
Newly diagnosed glioblastoma 
This trial is only available at MD Anderson
NIH link: NCT No: NCT02661282

Study: 2016-0252
Phase II
Treatment agent: VAL-083
Newly diagnosed MGMT unmethylated glioblastoma 
This trial is only available at MD Anderson
NIH link: NCT No: NCT02717962

Study: 2015-0953
Phase I
Treatment agent(s): BM-hMSCs-DNX-2401
Recurrent high-grade gliomas
This trial is only available at MD Anderson

Study: 2018-0045
Phase II
Treatment agent: ONC201
Recurrent high-grade gliomas with H3 K27M mutation
NIH link: NCT No: NCT03295396

Study: 2012-0358
Phase I
Treatment agent: WP1066
Recurrent malignant glioma and melanoma brain metastasis 
This trial is only available at MD Anderson
NIH link: NCT No: NCT01904123 

Study: 2017-0570
Phase I
Treatment agent: Ad-RTS-hIL-12 +Veledimex
Recurrent glioblastoma 
NIH link: NCT No: NCT02026271

Study: 2016-0252
Phase II
Treatment agent: VAL-083
Unmethylated MGMT recurrent glioblastoma
This trial is only available at MD Anderson
NIH link: NCT No: NCT02717962

Study: 2016-0433
Phase II
Treatment agent: Adenovirus (DNX-2401) with Pembrolizumab
Recurrent glioblastoma or gliosarcoma
NIH link: NCT No: NCT02798406

Study: 2014-0899
Phase I/II
Treatment agent(s): CMV-stimulated adoptive T cells,Temozolomide
Recurrent glioblastoma 
This trial is only available at MD Anderson
NIH link: NCT No: NCT02661282

Study: 2016-0443
Phase II
Treatment agents: Laser Interstitial Thermal Therapy and Lomustine
Recurrent glioblastoma or grade III IDH-wildtype anaplastic astrocytoma
This trial is only available at MD Anderson
NIH link: NCT03022578

Study: 2018-0045
Phase II
Treatment agent: ONC201
Recurrent high-grade gliomas with H3 K27M mutation
NIH link: NCT No: NCT03295396

Study: 2012-0358
Phase I
Treatment agent: WP1066
Recurrent malignant glioma and melanoma brain metastasis 
This trial is only available at MD Anderson
NIH link: NCT No: NCT01904123 

Study: 2016-0330
Phase III
Treatment agent: Lomustine and Eflornithine
First recurrence of grade III anaplastic astrocytoma
NIH link: NCT No: NCT02796261

Study: 2016-0859
Phase II
Treatment agent: Pembrolizumab
Recurrent malignant gliomas with a hypermutator phenotype
NIH link: NCT No: NCT02658279   

Study: #ALLIANCEA071601
Phase II
Treatment agent: Cobimetinib, Vemurafenib
BRAF V600E mutation positive Papillary Craniopharyngiomas
NIH link: NCT03224767

Study: 2012-0358
Phase I
Treatment agent: WP1066
Recurrent malignant glioma and melanoma brain metastasis 
This trial is only available at MD Anderson
NIH link: NCT No: NCT01904123 

Study: 2017-0615
Phase II
Treatment agent: Capecitabine, ONT-380, Trastuzumab
HER2-positive breast cancer with leptomeningeal disease
NIH link: NCT No: NCT03501979

Study: 2012-0441
Prospective assessment of correlative biomarkers in CNS patients (the PROACTIVE Program), a biomarker-driven program for clinical trial development for newly diagnosed and recurrent CNS patients